U.S. FDA declines to approve Y-mAbs's pediatric cancer drug

Y-mAbs Therapeutics

01/12/2022 22:39

Dec 1 (Reuters) - 
    The U.S. Food and Drug Administration on Thursday declined
to approve a treatment from Y-mAbs Therapeutics  YMAB.O  for a
rare form of nerve cancer in pediatric patients, dragging its
shares 15% lower in extended trade.
 (Reporting by Aditya Samal and Leroy Leo in Bengaluru; Editing
by Sriraj Kalluvila)
 ((Aditya.Samal@thomsonreuters.com;))